• Product Name(R)-Ruxolitinib (INCB018424)
• Brief DescriptionInhibitors
• Purification98.00%
• Biological ActivityRuxolitinib(INCB018424) is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3.
• Target NameJAK inhibitor
• CAS No. 941678-49-5
• Calculated MW 306.37
• Formulation C17H18N6
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cardiovascular System
  SMILES:C1CCC(C1)[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3
  Pathways:Angiogenesis; Chromatin/Epigenetic; JAK/STAT signaling; Stem Cells
  Receptor:JAK1; JAK2
  Boling pt:
  Melting pt:
  Solubility:DMSO: 61 mg/mL (199.1 mM)
  Appearance:White Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Quintas-Cardama A, et al. Blood, 2010, 115(15), 3109-3117.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting